Table 1 presents an overview of the various mechanisms through which HIF1α contributes to therapeutic resistance in cancer and points out about the importance of targeting these pathways to enhance treatment efficacy (65, 66, 68, 69). Cancer’s adeptness at evading therapeutic interventions poses a significant hurdle to effective These functions emphasize the necessity for therapeutic approaches that can circumvent or neutralize HIF1α’s protective effects (1, 13, 70, 71). The gene discussed is HIF1A; the disease is cancer.